How Telix landed a $2.1 billion radiopharma deal with Regeneron

How Telix landed a $2.1 billion radiopharma deal with Regeneron is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Alexandra Pecci · 2026-07-30

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.

Source: PharmaVoice